Acinetobacter spp. as causative agents of nosocomial infections in patients of intensive care unit
Abstract
During last decades, members of the genus acinetobacter cause serious nosocomial infections especially in intensive care units. The main sites of infection localization were the respiratory tract, blood-stream, surgical wounds. Data analysis showed an increase in the number of Acinetobacter spp. from 15,8 to 21,7 % in 2010 and 2015 respectively. All strains were resistant to most antibiotics and to carbapenems, too. Multiresistant hospital acquired bacteria, including acinetobacter, represent a serious public health issue rather than an individual hospital problem, and it would require an intensive coordinated effort to be effectively addressed.
About the Authors
T. V. Chernenkaya
Research Institute of Emergency Care n.a. N.V. Sklifosovsky
Russian Federation
Russian Federation
N. V. Evdokimova
Research Institute of Emergency Care n.a. N.V. Sklifosovsky
Russian Federation
Russian Federation
A. K. Shabanov
Research Institute of Emergency Care n.a. N.V. Sklifosovsky
Russian Federation
Russian Federation
D. A. Kosolapov
Research Institute of Emergency Care n.a. N.V. Sklifosovsky
Russian Federation
Russian Federation
A. A. Solodov
Research Institute of Emergency Care n.a. N.V. Sklifosovsky
Russian Federation
Russian Federation
References
1. Abbott I., Cerqueira G.M., Bhuiyan S., Peleg A.Y. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies // Expert Rev. Anti-Infect. Ther.- 2013. - Vol. 11, N 4. - P. 395-409.
2. Ayats J., Corbella X., Ardanuy C. et al. Epidemiological significance of cutaneous, pharnygeal and digestive tract colonization by multiresistant Acinetobacter baumanii in ICU patients // J. Hosp. Infect.- 1997. - Vol. 37, N 4.- P. 287-295.
3. Bach H., Berdichevsky Y., Gutnick D. An exocellular protein from the oil-degrading microbe Acinetobacter venetianus RAG-1 enhances the emulsifying activity of the polymeric bioemulsfier emulsan // Appl. Environ. Microbiol. - 2003. - Vol. 69, N 5. - P. 2608-2615.
4. Chang H.C., Chen Y.C., Lin M.C. et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator-associated pneumonia // J. Formos. Med. Assoc.- 2011. - Vol. 110, N 9. - P. 564-571.
5. Chen C.H., Lin L.C., Chang Y.J. et al. Infection Control Programs and Antibiotic Control Programs to Limit Transmission of Multi-Drug Resistant Acinetobacter bau-mannii Infections: Evolution of Old Problems and New Challenges for Institutes // Int. J. Environ. Res. Public Health. - 2015. - Vol. 12, N 8. - P. 8871-8882.
6. Chen M.Z., Hsueh P.R., Lee L.N. et al. Severe community-acquired pneumonia due to Acinetobacter baumannii // Chest - 2001. - Vol. 120, N 4. - P. 1072-1077.
7. Chuang Y.C., Sheng W.H., Li S.Y. et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia // Clin. Infect. Dis. - 2011. - Vol. 52, N 3.- P. 352-360.
8. Durante-Mangoni E., Signoriello G., Andini R. et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial // Clin. Infect. Dis. - 2013. - Vol. 57, N 3. - P. 349-358.
9. Espinal P., Seifert H., Dijkshoorn L. et al. Rapid and accurate identification of genomic species from the Acinetobacterbaumannii (Ab) group by MALDI-TOF MS // Clin. Microbiol. Infect. - 2012. - Vol. 18, N 11. - P. 1097-1103.
10. Eveillard M., Kempf M., Belmonte O. et al. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections // Int. J. Infect. Dis. - 2013. - Vol. 17, N 10. - P. e802-805.
11. Falagas M.E., Vardakas K.Z., Tsiveriotis K.P. et al. Effectiveness and safety of high-dose tige-cyclinecontaining regimens for the treatment of severe bacterial infections // Int. J. Antimicrob. Agents - 2014. - Vol. 44, N 1. - P. 1-7.
12. Gaddy J.A., Tomaras A.P., Actis L.A. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells // Infect. Immun. - 2009.-Vol. 77, N 8. - P. 3150-3160.
13. Gales A.C., Castanheira M., Jones R.N, Sader H.S. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010) // Diagn. Microbio.l Infect. Dis. - 2012.- Vol. 73, N 4.- P. 354-360.
14. Gallego J.L., Loredo J., Llamas J.F. et al. Bioremediation of dieselcontaminated soils: evaluation of potential in situ techniques by study of bacterial degradation // Biodegradation. - 2001. - Vol. 12, N 5.- P. 325-335.
15. Garcia-Garmendia J.L., Ortiz-Leyba C., Garnacho-Montero J. et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study // Clin. Infect. Dis. - 2001. - Vol. 33, N 7. - P. 939-946.
16. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline // J. Antimicrob. Chemother. - 2009.- Vol. 63, N 4. - P. 775-780.
17. Jones R.N., Flonta M., Gurler N. et al. Resistance surveillance program report for selected European nations (2011) // Diagn. Microbiol. Infect. Dis. - 2014. - Vol. 78, N 4.- P. 429-436.
18. Kim S.W., Cho C.H., Moon D.C. et al. Serum resistance of Acinetobacter bau-mannii through the binding of factor H to outer membrane proteins // FEMS Microbiol. Lett. - 2009. - Vol. 301, N 2. - P. 224-231.
19. Kofteridis D.P., Alexopoulou C., Valachis A. et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched casecontrol study // Clin. Infect. Dis. - 2010. - Vol. 51, N 11. - P. 1238-1244.
20. Kuo S.C., Chang S.C., Wang H.Y. et al. Emergence of extensively drug-resistant Acinetob acter b aumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program // BMC Infect. Dis. - 2012. - Vol. 12.- P. 200.
21. Liang W., Liu X.F., Huang J. et al. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients // BMC Infect. Dis. - 2011. - Vol. 11. - P. 109.
22. Ni W., Cui J., Liang B. et al. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii // J. Antibiot. (Tokyo). - 2013. - Vol. 66, N 12.- P. 705-708.
23. Rafei R., Kempf M., Eveillard M. et al. Current molecular methods in epidemiological typing of Acinetobacter baumannii // Future Microbiol. - 2014. - Vol. 9, N 10. - P. 1179-1194.
24. Sengstock D.M., Thyagarajan R., Apalara J. et al. Multidrug-Resistant Acinetobacter baumannii: An Emerging Pathogen among Older Adults in Community Hospitals and Nursing Homes // Clin. Infect. Dis. - 2010. - Vol. 50, N 12. - P. 1611-1616.
Review
For citations:
Chernenkaya T.V., Evdokimova N.V., Shabanov A.K., Kosolapov D.A., Solodov A.A. Acinetobacter spp. as causative agents of nosocomial infections in patients of intensive care unit. Medical alphabet. 2017;1(7):40-43. (In Russ.)
Views:
302
Email this article 